SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.
NCT ID: NCT06614322
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
190 participants
INTERVENTIONAL
2026-01-31
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC).
This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks.
Participants will:
* Undergo a quantitative sensory testing (QST) exam.
* Provide a blood sample.
* Complete questionnaires on the computer.
* Take the study drug as instructed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study
NCT06121232
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
NCT00385671
Pretreatment Identification of Duloxetine Success in Neuropathic Pain Patients
NCT01363284
A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)
NCT01533428
Pain-related Evoked Potentials in Unilateral Peripheral Nerve Injuries
NCT03082820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Period 1 - Placebo, Placebo, Duloxetine, Duloxetine, Pregabalin, Pregabalin
Participants will be randomized to 1 of the 6 possible treatment sequences
Pregabalin
300mg/day pregabalin capsule
Duloxetine
60mg/day duloxetine capsule
Placebo
Placebo capsule
Period 2 - Duloxetine, Pregabalin, Placebo, Pregabalin, Duloxetine, Placebo
Participants will be randomized to 1 of the 6 possible treatment sequences
Pregabalin
300mg/day pregabalin capsule
Duloxetine
60mg/day duloxetine capsule
Placebo
Placebo capsule
Period 3 - Pregabalin, Duloxetine, Pregabalin, Placebo, Placebo, Duloxetine
Participants will be randomized to 1 of the 6 possible treatment sequences
Pregabalin
300mg/day pregabalin capsule
Duloxetine
60mg/day duloxetine capsule
Placebo
Placebo capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
300mg/day pregabalin capsule
Duloxetine
60mg/day duloxetine capsule
Placebo
Placebo capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Between 18 and 80 years old (inclusive).
2. Have a diagnosis of peripheral neuropathic pain in both feet from generalized distal sensory polyneuropathy based on the following criteria
1. A history of a relevant lesion of the peripheral nervous system, disease, toxic exposure, or no known cause (i.e., idiopathic).
2. Pain distribution in a neuroanatomically plausible distribution consistent with a symmetrical generalized polyneuropathy (i.e., with a "glove and stocking" distal to proximal gradient).
3. DN4 score≥ 4
3. Have experienced the neuropathic pain in the feet for at least 6 months.
4. Have at least one of the following sensory signs upon clinical examination: abnormal pinprick perception, allodynia, hyperalgesia, abnormal light touch perception, abnormal vibratory perception, or abnormal proprioception.
5. Have average daily baseline worst pain intensity in their feet of 4 or greater and less than 10, on a 0-10 numeric rating scale of pain intensity (0 = "no pain," 10= "most intense pain imaginable") as measured on the daily diary during screening from at least 5 measurements.
6. Able to understand and read English. This requirement is to ensure that participants can provide informed consent and complete PROs.
7. Have been on stable dosages of all pain medications or using all non-pharmacologic treatments for neuropathy pain at consistent frequency for at least 1 month and willing and able to stay on those dosages (or use those frequencies) (except acetaminophen rescue) throughout the duration of the study.
8. Willing and able to complete electronic patient-reported outcomes at home using a REDCap link.
Exclusion Criteria
1. Taking any opioid medication with a daily mean morphine equivalent (MME) of \> 30.
2. Have a different diagnosis of pain in the feet including but not limited to musculoskeletal pain (e.g., foot arthritis, plantar fasciitis) or lumbar sacral radiculopathy that they rate to be worse than their neuropathic pain in their feet, or that in the opinion of the investigator, precludes the participant from rating their neuropathy pain in their feet.
3. Have a central cause of neuropathic pain (e.g., demyelinating disease, spinal cord injury, Parkinson's disease).
4. Have a history of an inciting traumatic or surgical cause that corresponds with the development of features consistent with a peripheral neuropathy.
5. Bilateral polyradiculopathy, with a distal distribution (i.e., symptoms extending into the feet).
6. History of acute polyneuropathy (e.g., Guillain-Barre Syndrome, acute motor sensory axonal neuropathy \[AMSAN\]) within 6 months prior to Visit 1.
7. Have autoimmune-mediated neuropathy (e.g., RA, lupus, Sjogren syndrome, Lyme disease, chronic inflammatory demyelinating polyneuropathy (CIDP)) unless the associated inflammation is controlled and, in the opinion of the investigator, is expected to remain stable throughout the course of the study.
8. Charcot-Marie-Tooth disease in which nociceptive pain from joint deformity confounds assessment of neuropathic pain.
9. Have taken the treatment that caused the participant's neuropathy (e.g., neurotoxic chemotherapy, certain HIV therapies) less than 6 months prior to Visit 1.
10. Have taken duloxetine (at least 60mg/day) in the past 6 months or have taken duloxetine at any dosage within a week prior to the screening visit.\*\*
11. Have taken pregabalin (at least 300mg/day) OR gabapentin (at least 1200mg/day) in the past 6 months or have taken pregabalin or gabapentin at any dosage within a week prior to the screening visit.##
12. Have ever previously taken BOTH pregabalin (or gabapentin) AND duloxetine at sufficient dosages and for a sufficient length of time that, in the opinion of the investigator, the participant should have experienced pain relief if they were going to respond, but they did not receive benefit from EITHER drug.
13. Taking venlafaxine, buproprion, tramadol, or St. John's Wort. Concomitant use of one medication that inhibits the reuptake of serotonin is allowed at certain dosages. (See Appendix A for maximum allowed dosages for common selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs); maximum dosages for other applicable drugs will be decided by the research team leadership composed of a) clinical pharmacist with extensive experience in chronic pain management, b) a physician board-certified in pain medicine and psychiatry, and c) a board-certified neurologist.\*\*
14. Taking a monoamine oxidase inhibitor.\*\*
15. Taking CYP1A2 inhibitors or thioridazine.
16. Have a spinal cord stimulator.
17. Have an active, uncontrolled/unstable medical condition (e.g., neurological, gastrointestinal, renal, hepatic, cardiovascular, pulmonary, metabolic, endocrine, hematological, genitourinary, cancer, or other major disorder), psychotic disorder or any other uncontrolled psychiatric illness that in the opinion of the investigator makes it unsafe to participate or inclusion of the participant will have a negative effect on the study.
18. Had a clinically significant illness or operative procedure within four weeks of screening.
19. Known hypersensitivity to pregabalin. ##
20. Known hypersensitivity to duloxetine.\*\*
21. Known history of chronic kidney disease that in the opinion of the investigator would make it unsafe to participate.
22. Known history of chronic liver disease that in the opinion of the investigator would make it unsafe to participate.
23. Excessive consumption of alcohol (i.e., more than 5 drinks / day for males and more than 4 drinks / day for females).
24. A history of illicit drug use in the past year or planning to take any illicit drugs during the course of the study, including cannabis or marijuana at varying amounts for recreational use.
25. Patients who are at significant risk of suicide, or are a danger to self or others, in the opinion of the investigator, based upon clinical interview and the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening and baseline. Affirmative answer to suicidal ideation questions 4 or 5, within the last 6 months and / or suicidal behavior (actual attempt, interrupted attempt, aborted attempt, and/or preparatory acts/behavior) within the last 2 years are exclusionary.
26. Evidence of cognitive impairment including dementia or a psychiatric condition (e.g., schizophrenia, bipolar disorder) that may interfere with the subject's ability to complete assessments.
27. Amputation of lower limbs (foot, ankle, leg, or thigh). Isolated toe amputations are permitted.
28. Pregnant or planning to become pregnant during the study period or breastfeeding (screened via self-report).
29. Enrolled in another investigational medication trial or a trial of any intervention for pain in your feet.
30. Unable or unwilling to provide informed consent.
31. Any additional reason that, in the opinion of the site investigator, would make it unsafe to participate or inclusion of the participant would hurt the study.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beth Israel Deaconess Medical Center
OTHER
University of Rochester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jennifer Gewandter
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer Gewandter, PhD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beth Israel Deaconess Medical Center for Autonomic and Peripheral Nerve Disorders
Boston, Massachusetts, United States
Ichan School of Medicine at Mount Sinai
New York, New York, United States
University of Rochester
Rochester, New York, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
University of Utah
Salt Lake City, Utah, United States
University of Vermont
Burlington, Vermont, United States
VCU Medical Center
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00009806
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.